Automated Organization ProfileCardiovascular Research Center
Cardiovascular Research Center
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets in this organization
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the organization's datasets
Total Mentions
Total mentions of the organization's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 1.0 (sum of 4 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
We conducted systematic review and meta-analysis to provide a comprehensive overview of outcomes in patients who underwent personalized genomics-based versus non-personalized treatment in oncology. The PubMed searches detected 803 studies based on phase II clinical trials’ results published from 2010 to 2021. We selected 50 studies, having 81 arms and 6536 patients for the analysis. We compared Response Rate (RR), medians and 1-year rates of Overall Survival (OS) and Progression-Free Survival (PFS) between genomics-based personalized and non-personalized arms. This repository contains final dataset (Dataset file) and the information on 803 studies identified in the literature search (803 studies description file). The searches, study selection, data extraction and synthesis were performed in accordance to PRISMA (preferred reporting items for systematic review and meta-analysis) guidelines. The research protocol was registered in PROSPERO (International prospective register of systematic reviews, https://www.crd.york.ac.uk/PROSPERO), record ID CRD42024504021. We performed proportional meta-analysis using the RStudio program, utilizing the R programming language and packages "meta", "metafor," and "tidyverse", the code is available at github: https://github.com/MikhailPot/PreciseOnco_meta-analysis
Authors
- Potievskiy, Mikhail B. ;
- Zharova, Elena P. ;
- Nekrasova, Lidia A. ;
- Garifullin, Airat I. ;
- Korobov, Ivan V. ;
- Shevchenko, Nikita E. ;
- Zabolotneva, Anastasia A. ;
- Atochin, Dmitriy N. ;
- Kaprin, Andrei D. ;
- Shegai, Peter V.
We conducted systematic review and meta-analysis to provide a comprehensive overview of outcomes in patients who underwent personalized genomics-based versus non-personalized treatment in oncology. The PubMed searches detected 803 studies based on phase II clinical trials’ results published from 2010 to 2021. We selected 50 studies, having 81 arms and 6536 patients for the analysis. We compared Response Rate (RR), medians and 1-year rates of Overall Survival (OS) and Progression-Free Survival (PFS) between genomics-based personalized and non-personalized arms. This repository contains final dataset (Dataset file) and the information on 803 studies identified in the literature search (803 studies description file). The searches, study selection, data extraction and synthesis were performed in accordance to PRISMA (preferred reporting items for systematic review and meta-analysis) guidelines. The research protocol was registered in PROSPERO (International prospective register of systematic reviews, https://www.crd.york.ac.uk/PROSPERO), record ID CRD42024504021. We performed proportional meta-analysis using the RStudio program, utilizing the R programming language and packages "meta", "metafor," and "tidyverse", the code is available at github: https://github.com/MikhailPot/PreciseOnco_meta-analysis
Authors
- Potievskiy, Mikhail B. ;
- Zharova, Elena P. ;
- Nekrasova, Lidia A. ;
- Garifullin, Airat I. ;
- Korobov, Ivan V. ;
- Shevchenko, Nikita E. ;
- Zabolotneva, Anastasia A. ;
- Atochin, Dmitriy N. ;
- Kaprin, Andrei D. ;
- Shegai, Peter V.
We conducted systematic review and meta-analysis to provide a comprehensive overview of outcomes in patients who underwent personalized genomics-based versus non-personalized treatment in oncology. The PubMed searches detected 803 studies based on phase II clinical trials’ results published from 2010 to 2021. We selected 50 studies, having 81 arms and 6536 patients for the analysis. We compared Response Rate (RR), medians and 1-year rates of Overall Survival (OS) and Progression-Free Survival (PFS) between genomics-based personalized and non-personalized arms. This repository contains final dataset. The searches, study selection, data extraction and synthesis were performed in accordance to PRISMA (preferred reporting items for systematic review and meta-analysis) guidelines. The research protocol was registered in PROSPERO (International prospective register of systematic reviews, https://www.crd.york.ac.uk/PROSPERO), record ID CRD42024504021. We performed proportional meta-analysis using the RStudio program, utilizing the R programming language and packages "meta", "metafor," and "tidyverse", the code is available at github: https://github.com/MikhailPot/PreciseOnco_meta-analysis
Authors
- Potievskiy, Mikhail B. ;
- Zharova, Elena P. ;
- Nekrasova, Lidia A. ;
- Garifullin, Airat I. ;
- Korobov, Ivan V. ;
- Shevchenko, Nikita E. ;
- Zabolotneva, Anastasia A. ;
- Atochin, Dmitriy N. ;
- Kaprin, Andrei D. ;
- Shegai, Peter V.
We conducted systematic review and meta-analysis to provide a comprehensive overview of outcomes in patients who underwent personalized genomics-based versus non-personalized treatment in oncology. The PubMed searches detected 873 studies based on phase II clinical trials’ results published from 2010 to 2021. We selected 46 studies, having 81 arms and 6536 patients for the analysis. We compared Response Rate (RR), medians and 1-year rates of Overall Survival (OS) and Progression-Free Survival (PFS) between genomics-based personalized and non-personalized arms. This repository contains final dataset. The searches, study selection, data extraction and synthesis were performed in accordance to PRISMA (preferred reporting items for systematic review and meta-analysis) guidelines. The research protocol was registered in PROSPERO (International prospective register of systematic reviews, https://www.crd.york.ac.uk/PROSPERO), record ID CRD42024504021. We performed proportional meta-analysis using the RStudio program, utilizing the R programming language and packages "meta", "metafor," and "tidyverse", the code is available at github: https://github.com/MikhailPot/PreciseOnco_meta-analysis
Authors
- Potievskiy, Mikhail B. ;
- Zharova, Elena P. ;
- Nekrasova, Lidia A. ;
- Garifullin, Airat I. ;
- Korobov, Ivan V. ;
- Shevchenko, Nikita E. ;
- Zabolotneva, Anastasia A. ;
- Atochin, Dmitriy N. ;
- Kaprin, Andrei D. ;
- Shegai, Peter V.